CHAPTER 15 : Mastering Nephrolithiasis: From Diagnosis to Long-Term Prevention Strategies

Learning objectives

By the end of this chapter, the learner should be able to distinguish uncomplicated renal colic from an infected or high-risk obstructed system; interpret urinalysis, culture, imaging, and stone composition in context; select safe analgesia and medical expulsive therapy; coordinate urgent decompression and definitive stone treatment; perform a risk-based metabolic evaluation; and prescribe individualized dietary and pharmacologic prevention while accounting for CKD, hyperkalemia risk, pregnancy, transplant status, and medication toxicity.

15.1 Clinical frame and epidemiology

Nephrolithiasis is a systemic and recurrent disease rather than an isolated episode of ureteral pain. Stones form when urine is supersaturated with calcium oxalate, calcium phosphate, uric acid, cystine, or infection-related magnesium ammonium phosphate. Risk is influenced by urine volume, sodium and animal-protein intake, calcium and oxalate handling, obesity and insulin resistance, bowel disease or bariatric surgery, medications, inherited disorders, and the anatomy and microbiology of the urinary tract. Recurrent stones are associated with hypertension, diabetes, CKD, cardiovascular disease, and bone disease; prevention should therefore be integrated with overall cardiometabolic and kidney care.[1] [2]

A first stone does not automatically require an extensive metabolic work-up, but every patient should receive basic evaluation and stone analysis when material is available. Recurrent, bilateral, pediatric, early-onset, infection-related, cystine, uric-acid, solitary-kidney, CKD-associated, drug-related, or anatomically complicated stone disease is high risk and warrants specialist metabolic assessment.

Specialist framing: the immediate question is not simply “Is there a stone?” but “Is there infection, obstruction, threatened renal function, a need for urgent drainage, and a preventable biochemical driver?”

15.2 Stone composition and clinical implications

The original percentage labels commonly used for calcium, uric-acid, struvite, and cystine stones are approximate and vary by population, laboratory method, and referral setting. Composition should be reported from infrared spectroscopy or X-ray diffraction rather than inferred from radiographic appearance alone.

15.3 Pathophysiology and risk phenotype

Supersaturation is the central physicochemical driver. Nucleation is followed by crystal growth, aggregation, transport, and retention on papillary surfaces or within obstructed collecting systems. Randall plaques may provide a substrate for calcium oxalate attachment, whereas ductal plugging and intratubular crystal retention are important in calcium phosphate disease. Citrate, magnesium, pyrophosphate, adequate urine volume, and normal urinary flow inhibit crystallization, but their effect is modified by pH, ionic strength, and competing solutes.

Clinical phenotyping should include diet, fluid access, occupation, climate, bowel disease, bariatric surgery, recurrent UTI, gout, hyperparathyroidism, distal RTA, osteoporosis, CKD, transplant status, family history, and medications. Topiramate can increase urine pH and reduce citrate; loop diuretics can increase calciuria; high-dose vitamin C can increase oxalate; protease inhibitors may produce drug stones; and carbonic anhydrase inhibition may promote calcium phosphate risk.

15.4 Presentation and urgent triage

Renal colic typically causes abrupt flank or abdominal pain radiating toward the groin, with nausea, vomiting, diaphoresis, and marked restlessness. Dysuria and frequency may occur when a distal ureteral stone irritates the bladder. Gross or microscopic hematuria is common but is not obligatory; its absence does not exclude a stone. Fever, rigors, hypotension, tachycardia, altered mental status, leukocytosis, pyuria, bacteriuria, or rising creatinine should raise concern for infection or threatened renal function.

Immediate urologic consultation is required for suspected infected obstruction, anuria, bilateral obstruction, obstruction in a solitary functioning kidney, progressive AKI, uncontrolled pain or vomiting, sepsis, pregnancy with concerning obstruction, or inability to maintain oral intake. An infected obstructed system requires resuscitation, cultures, broad empiric antibiotics adjusted to local resistance patterns, and urgent decompression with ureteral stent or nephrostomy. Definitive stone removal is deferred until sepsis and metabolic instability are controlled.

Initial assessment

Obtain vital signs, pain and vomiting severity, hydration status, abdominal and costovertebral examination, medication history, pregnancy status when relevant, prior stone composition, prior cultures, and baseline renal function. Urinalysis should include dipstick and microscopy; obtain urine culture when there is pyuria, bacteriuria, systemic illness, recurrent infection, an obstructed system, or planned intervention. Check CBC, creatinine/eGFR, electrolytes, bicarbonate, calcium, and uric acid when clinically indicated. Measure PTH when hypercalcemia is present or suspected. In severe infection, add lactate and blood cultures.

Imaging

Ultrasound is an appropriate radiation-sparing first test in pregnancy, children, and selected adults, and can identify hydronephrosis and some renal stones. In adults with suspected acute stone disease, low-dose non-contrast CT provides the most accurate assessment of stone size, location, density, obstruction, alternative diagnoses, and complex anatomy; use a dose-optimized protocol and avoid unnecessary repeat exposure. A KUB radiograph can support follow-up of radiopaque stones but is insufficient as a stand-alone diagnostic study. Contrast-enhanced imaging may be necessary when evaluating an alternative diagnosis, renal perfusion, abscess, or complex anatomy; kidney function and diagnostic urgency should guide contrast decisions.

Stone analysis and metabolic evaluation

Send every recovered stone or surgical fragment for composition analysis. For recurrent or high-risk stone formers, obtain serum calcium, creatinine, bicarbonate, uric acid, phosphate, and PTH when indicated, plus two consecutive 24-hour urine collections when feasible. Measure volume, calcium, oxalate, citrate, uric acid, sodium, potassium, pH, creatinine, and supersaturation indices. Interpret collections only after the patient has resumed usual diet and fluid intake; a single abnormal collection should be confirmed when the result will change long-term treatment.

15.6 Acute management of renal colic

NSAIDs are generally first-line analgesics when there is no contraindication because they reduce prostaglandin-mediated ureteral pressure and often outperform opioids for renal-colic pain. In CKD, AKI, volume depletion, active gastrointestinal bleeding, anticoagulation-related risk, heart failure, or severe hypertension, NSAIDs may be unsafe; use the lowest effective dose or an alternative analgesic and reassess renal function. Opioids are rescue therapy for severe pain not controlled or not safely treated with NSAIDs, with antiemetic support and monitoring for respiratory depression.

Routine forced IV hydration does not accelerate stone passage and may worsen pressure and pain. Correct clinically important dehydration, but use isotonic fluid judiciously. Antiemetics, oral intake as tolerated, and a documented plan for reassessment are often more useful than indiscriminate fluid loading.

Medical expulsive therapy

The 2026 AUA surgical guideline strongly recommends offering an alpha-adrenergic blocker for approximately 30 days to adults and children with distal ureteral stones ≤10 mm when expectant management is appropriate. For adult middle or proximal ureteral stones ≤10 mm, MET may be offered conditionally. Benefit is greatest when spontaneous passage remains plausible and appears more consistent for distal stones, particularly those >5 mm. Discuss hypotension, dizziness, drug interactions, and off-label status where applicable. MET is not a substitute for drainage in infection, worsening renal function, refractory symptoms, or an unlikely passage pathway. Confirm stone passage or clearance with follow-up imaging when passage is uncertain.

15.7 Definitive intervention and peri-procedural nephrology

Treatment selection depends on size, location, composition, anatomy, renal function, symptoms, infection status, patient preference, stone-free goals, bleeding risk, pregnancy, and local expertise. Ureteroscopy and shockwave lithotripsy are options for many ureteral stones, while PCNL is first-line for renal stones >2 cm and is particularly appropriate for staghorn or complex stone burden. For 1–2 cm renal stones, mini-PCNL may provide higher stone-free rates than URS in selected patients, at the cost of greater invasiveness; shared decision-making is essential. For lower-pole stones, anatomy and fragment clearance influence the choice between SWL, URS, and percutaneous approaches.

Before definitive surgery, obtain urinalysis and/or culture, assess renal function and bleeding risk, and treat untreated bacteriuria or funguria according to the procedural plan. Do not proceed with definitive stone surgery in an untreated infected system. PCNL planning generally requires pre-operative CT and assessment of differential renal function when clinically relevant. Antithrombotic management requires individualized urology, nephrology, and peri-operative planning.

15.8 Recurrent stone prevention

The universal target is a urine volume of at least 2.5 L/day, achieved through distributed fluid intake and adjusted for climate, occupation, heart failure, CKD, and dialysis prescription. Avoid excessive sugar-sweetened beverages. Maintain normal dietary calcium, usually about 1,000–1,200 mg/day for adults unless a separate clinical indication requires modification, and consume calcium with meals to bind intestinal oxalate. Restrict sodium rather than calcium; a practical target is approximately <2,300 mg sodium/day when compatible with the patient’s cardiovascular and kidney plan. Moderate animal protein, increase fruit and vegetables when potassium and acid-base status permit, and avoid extreme dietary patterns.

Calcium oxalate and calcium phosphate

For hypercalciuria, reduce sodium, maintain normal dietary calcium, and consider a thiazide or thiazide-like diuretic with monitoring of sodium, potassium, glucose, uric acid, and kidney function. Potassium citrate is appropriate for hypocitraturia, but in CKD or hyperkalemia risk consider serum potassium, bicarbonate, eGFR, and alternatives such as sodium-based alkali only with careful sodium-risk assessment. In enteric hyperoxaluria, treat the bowel disorder, use calcium with meals, reduce high-oxalate foods, and consider specialized therapy for severe disease. Suspected primary hyperoxaluria warrants genetic and metabolic referral.

Uric acid

Low urine pH is usually the dominant abnormality. Potassium citrate is first-line for prevention and may dissolve uric-acid stones when urine pH is monitored and maintained approximately in the 6.0–6.5 range for prevention and often 6.5–7.0 for dissolution under specialist supervision. Avoid excessive alkalinization that promotes calcium-phosphate precipitation. Allopurinol is reserved for selected patients with hyperuricosuria or recurrent uric-acid stones despite appropriate alkalinization, not as a replacement for correcting acidic urine.

Infection stones

Struvite or carbonate-apatite stones require culture-directed antimicrobial therapy and complete stone clearance whenever feasible. Antibiotics alone do not reliably eradicate bacteria protected within a stone. Urease inhibitors such as acetohydroxamic acid have limited, highly selected use because of adverse effects and should be managed by experienced specialists. Persistent infection, obstruction, residual fragments, and infected hardware should prompt a source-control review.

Cystinuria

Use very high fluid intake, often targeting urine volume >3 L/day in adults when safe, frequent daytime and nighttime hydration, dietary sodium reduction, and alkalinization with a usual urine-pH goal ≥7.0 while monitoring calcium-phosphate risk. If cystine remains above the solubility threshold or stones recur, use a thiol-binding agent such as tiopronin or another specialist-selected therapy, with monitoring for adverse effects and proteinuria.

Follow-up

Recheck serum chemistry and 24-hour urine parameters after initiating preventive therapy, commonly within several months, then at individualized intervals. Repeat imaging to confirm clearance, monitor residual stones, and assess hydronephrosis. Escalate evaluation for recurrent stones despite adherence, rapid stone growth, persistent infection, declining eGFR, nephrocalcinosis, or suspected inherited disease.

15.9 CKD, transplant, pregnancy, and special populations

In CKD, avoid reflexive NSAID use, adjust analgesics and antibiotics, and interpret urinary excretion values in the context of reduced GFR. Potassium-containing citrate may be unsafe in advanced CKD or hyperkalemia. Patients with a solitary kidney, transplant kidney, or rapidly changing renal function require a lower threshold for imaging, urology consultation, and decompression. In pregnancy, ultrasound is first-line; MRI without gadolinium may be considered when ultrasound is nondiagnostic, and CT is reserved for situations in which the result will change urgent management. Surgical and analgesic decisions should follow multidisciplinary obstetric–urologic protocols.

15.10 Summary

Nephrolithiasis management is a sequence: triage for infection and threatened renal function; diagnose with appropriate laboratory tests and dose-optimized imaging; relieve pain without worsening kidney injury; use MET only when passage is plausible; decompress infected obstruction urgently; select definitive treatment by size, location, anatomy, and patient factors; analyze every recovered stone; and prevent recurrence using urine-volume, sodium, calcium, diet, and targeted pharmacologic interventions.

Clinical pearls

1. Fever or systemic illness with obstruction is a drainage emergency, not an outpatient MET problem.
2. Hematuria may be absent; a negative dipstick does not exclude a stone.
3. Ultrasound is radiation-sparing; low-dose non-contrast CT is the most accurate adult test when diagnostic certainty or complication assessment matters.
4. The 2026 AUA recommendation for MET is approximately 30 days for distal ureteral stones ≤10 mm; benefit is not uniform across all stone locations.
5. Never treat a 680-pixel table as mobile-safe unless horizontal scrolling is confined to a wrapper.
6. Normal dietary calcium with meals is protective for calcium oxalate stone formers; severe calcium restriction can increase oxalate absorption.
7. Urine pH, not serum uric acid alone, is the dominant therapeutic target in uric-acid stone disease.
8. Residual fragments after infection-stone surgery may represent persistent infection risk; source control matters.

Case 1: Obstructed infection

A patient with diabetes has fever, rigors, flank pain, creatinine rising from 1.1 to 2.4 mg/dL, pyuria, and CT evidence of a proximal ureteral stone with hydronephrosis. The correct next step is blood and urine cultures, sepsis treatment, broad empiric antibiotics, and urgent ureteral stent or nephrostomy. Definitive stone removal waits until infection is controlled.

Case 2: Recurrent calcium oxalate stones

A recurrent stone former has urine volume 1.4 L/day, calcium 330 mg/day, sodium 220 mmol/day, citrate low-normal, and normal serum calcium. First-line management is increased fluid intake, sodium reduction, normal calcium with meals, and reassessment before or alongside a thiazide if hypercalciuria persists. The result should not prompt calcium restriction.

Case 3: Uric-acid dissolution

A patient with radiolucent stones has urine pH 5.1 and metabolic syndrome. Potassium citrate with home pH monitoring and dietary modification is prioritized. Allopurinol is considered only if significant hyperuricosuria persists or stones recur despite adequate alkalinization.

Case 4: CKD and analgesia

A patient with eGFR 24 mL/min/1.73 m², vomiting, and a 5-mm distal stone presents without infection. NSAIDs may worsen renal perfusion in the setting of volume depletion and advanced CKD. Use cautious rehydration, renal-safe analgesic planning, antiemetics, and early reassessment rather than automatic ketorolac dosing.

Case 5: Cystinuria

A young adult with recurrent bilateral stones has hexagonal crystals and cystine on analysis. Management includes genetic/metabolic referral, urine volume often >3 L/day, sodium restriction, urine-pH monitoring ≥7.0, and thiol-binding therapy if cystine remains supersaturated.

Question 1

A patient has fever, hypotension, pyuria, and an obstructing ureteral stone. What is the priority?

A. Tamsulosin and outpatient review
B. Forced IV hydration only
C. Urgent drainage plus cultures, resuscitation, and antibiotics
D. Immediate definitive ureteroscopy during sepsis

Answer: C. Infected obstruction requires source control. Definitive stone treatment is delayed until sepsis and physiologic instability improve.

Question 2

Which statement best reflects current MET guidance?

A. Alpha-blockers should be used for every renal stone
B. Alpha-blockers are strongly recommended for approximately 30 days for distal ureteral stones ≤10 mm when expectant management is appropriate
C. Alpha-blockers replace follow-up imaging
D. Alpha-blockers are indicated in infected obstruction

Answer: B. Benefit is location- and size-dependent; MET does not replace drainage or follow-up.

Question 3

A recurrent calcium oxalate former has high urinary sodium and calcium. Which intervention is most appropriate initially?

A. Severe dietary calcium restriction
B. Normal calcium with meals and sodium reduction
C. High-dose vitamin C
D. Eliminate all fruits and vegetables

Answer: B. Sodium reduction lowers calciuria, while normal dietary calcium with meals limits oxalate absorption.

Question 4

A patient with radiolucent stones has urine pH 5.0. The most important preventive target is:

A. Urine alkalinization with monitored pH
B. Calcium restriction
C. Long-term antibiotics
D. Urine acidification

Answer: A. Low urine pH drives uric-acid precipitation; alkalinization is the principal therapy.

Question 5

Which statement about stone analysis is correct?

A. It is unnecessary after the first episode
B. Composition can be reliably inferred from KUB appearance
C. Recovered stones should be analyzed because composition changes prevention
D. Only staghorn stones require analysis

Answer: C. Analysis identifies calcium, uric-acid, infection, cystine, drug-related, and mixed phenotypes.

Question 6

A patient with eGFR 22 has renal colic and volume depletion. Which analgesic principle is safest?

A. Give repeated NSAID doses without reassessment
B. Avoid considering kidney function because the obstruction is unilateral
C. Correct volume depletion and individualize analgesia; NSAIDs may be unsafe
D. Use forced fluids to drive the stone out

Answer: C. Advanced CKD and volume depletion increase NSAID-associated kidney risk.

Question 7

A 2.5-cm staghorn calculus remains after antibiotic treatment. What is the central management principle?

A. Suppressive antibiotics alone
B. Complete surgical clearance and culture-directed infection management
C. Immediate thiazide therapy
D. Urine acidification alone

Answer: B. Infection stones require source control whenever feasible.

Question 8

Which patient most clearly warrants a full metabolic evaluation?

A. A single uncomplicated stone with no risk factors
B. Recurrent bilateral stones with a family history and CKD
C. Any patient with microscopic hematuria
D. A patient with an incidental 2-mm renal calculus and no history

Answer: B. Recurrent, bilateral, inherited, and CKD-associated disease is high risk.

Question 9

What is the preferred initial imaging strategy for a pregnant patient with suspected renal colic?

A. Routine contrast CT
B. Ultrasound, with multidisciplinary escalation if nondiagnostic and management-changing
C. KUB radiograph first
D. No imaging until delivery

Answer: B. Ultrasound is radiation-sparing; MRI or carefully justified CT may follow when needed.

Question 10

A patient with cystinuria continues to form stones despite a urine volume of 2 L/day and urine pH 6.5. What is the next specialist strategy?

A. Reduce fluid intake
B. Increase fluid target, alkalinize toward ≥7.0, and consider thiol-binding therapy
C. Start allopurinol alone
D. Restrict dietary calcium severely

Answer: B. Cystine requires very high dilution and alkalinization; thiol-binding agents are used for persistent supersaturation or recurrence.

References

1. EAU Guidelines on Urolithiasis 2026
2. AUA Medical Management of Kidney Stones Guideline 2026
3. AUA Surgical Management of Kidney and Ureteral Stones Guideline 2026
4. AUA 2026 Medical Management Guideline announcement
5. NICE: Renal and ureteric stones—assessment and management